Role of pegylated interferon-α-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 5, 2008, Pages 573-580

  Lopez Cortes, L F ^a,c   Valera Bestard, B ^a   Gutierrez Valencia, A ^a   Ruiz Valderas, R ^a   Jimenez, L ^a   Arizcorreta, A ^b   Terron A ^a   Viciana, P ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c HOSPITAL DE JEREZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INDIVIDUALIZATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD;

EID: 54249130658     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.110     Document Type: Article

References (37)

1. Strader, D.B., Wright, T., Thomas, D.L. & Seeff, L.B; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. AASLD practice guideline. Hepatology 39, 1147-1171 (2004).
2. Soriano, V. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21, 1073-1089 (2007).
3. Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
4. Heathcote, E.J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673-1680 (2000).
5. Zeuzem, S. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672 (2000).
6. Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
7. Torriani, F.J. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351, 438-450 (2004).
8. Glue, P. et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68, 556-567 (2000).
9. Lindsay, K.L. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395-403 (2001).
10. Hadziyannis, S.J. et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
11. Pockros, P.J. et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am. J. Gastroenterol. 99, 1298-1305 (2004).
12. Shiffman, M.L. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124-134 (2007).
13. Xu, Z.X., Hoffman, J., Patell, M.R. & Joubert, P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-interferon) and interferon α-2a to healthy subjects. Hepatology 28 (suppl. 2), 702 (1998).
14. Modi, M. et al. The pharmacokinetic behavior of pegylated (40 kD) interferon alfa-2a in chronic hepatitis C patients after multiple dosing. Hepatology 32 (suppl. 1), 394A (2000).
15. Guo, J.T., Bichko, V.V. & Seeger, C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75, 8516-8523 (2001).
16. Kato, T. et al. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J. Clin. Microbiol. 43, 5679-5684 (2005).
17. Buti, M. et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 35, 930-936 (2002).
18. Formann, E., Jessner, W., Bennett, L. & Ferenci, P. Twice weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Viral Hepat. 10, 271-276 (2003).
19. Talal, A.H. et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43, 943-953 (2006).
20. Asahina, Y. et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J. Viral Hepat. 14, 396-403 (2007).
21. Di Bisceglie, A.M., Fan, X., Chambers, T. & Strinko, J. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J. Med. Virol. 78, 446-451 (2006).
22. Lindahl, K., Schvarcz, R., Bruchfeld, A. & Stahle, L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J. Viral Hepat. 11, 84-87 (2004).
23. Rendon, A.L. et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/Hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr. 39, 401-405 (2005).
24. Nuñez, M. et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir. Ther. 10, 657-662 (2005).
25. Arase, Y. et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 48, 138-144 (2005).
26. Souvignet, C., Stanke-Labesque, F., Bronowicki, J.P., Larrat, S., Quesada, J.L. & Zarski, J.P. Evidence that serum ribavirin steady-state concentrations do not correlate with early virological response during peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C. J. Hepatol. 42 (suppl. 2), 22 (2005).
27. Ferenci, E. et al. Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40kd) plus ribavirin: interim results of a randomised controlled trial. J. Hepatol. 44, S37 (2006).
28. Donnerer, J. et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 76, 136-140 (2006).
29. Diago, M. et al. High-dose peginterferon alfa-2a [40 kD] plus ribavirin improves viral response rate in patients with chronic hepatitis C genotype 1 non-responders to previous combined therapy: a Spanish pilot study. Hepatology 39, 451A (2004).
30. Marcellin, P. et al. Retreatment with Pegasys® in patients not responding to prior peginterferon alfa-2b/ribavirin combination therapy - efficacy analysis of the 12-week induction period of the REPEAT study. Hepatology 42, 749A (2005).
31. Washenberger, C.L., Han, J.Q., Kechris, K.J., Jha, B.K., Silverman, R.H. & Barton, D.J. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res. 130, 85-95 (2007).
32. Dal Pero, F. et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J. Infect. Dis. 196, 998-1005 (2007).
33. Fujiwara, D. et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J. Viral Hepat. 11, 136-140 (2004).
34. Reddy, K.R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 33, 433-438 (2001).
35. Scheuer, P.J. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 13, 372-374 (1991).
36. Garrison, T.L., Hung, F., Izotova, L., Schwartz, B., Lavoie, T. & Lee-Own, F.V. ELISA measurement of interferons. Biotechniques (suppl.), 98-100 (2002).
37. Larrat, S., Stanke-Labesque, F., Plages, A., Zarski, J.P., Bessard, G. & Souvignet, C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 47, 124-129 (2003).